bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Bronchitis%20-%20chronic%20in%20acute%20exacerbation Management

Prevention

Influenza Vaccine

  • The use of an annual influenza vaccine for all patients with chronic bronchitis is strongly recommended
    • Patients with chronic lung disease have a higher risk of complications from influenza infection
    • Annual influenza vaccination decreases the morbidity and mortality of influenza in the elderly by 50%
  • Please see Influenza disease management chart for further information

Pneumococcal Vaccine

  • It is recommended that pneumococcal vaccine be administered at least once to patients with chronic bronchitis
    • Consider repeating vaccine every 5-10 years in high-risk patients
  • Pneumococcal vaccine is safe and may reduce invasive pneumococcal infection in patients with COPD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 5 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Jairia Dela Cruz, 03 Aug 2020
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.